All relevant data are within the paper and figures.

Introduction {#sec005}
============

Lung cancer is the leading cause of malignancy-related mortality in both developed and developing countries, and non-small cell lung cancer (NSCLC) accounted for approximately 80% of all lung cancer deaths \[[@pone.0144663.ref001], [@pone.0144663.ref002]\]. Despite the tremendous development of technique, lung cancer remains dissatisfactory improvement in survival during the past decades \[[@pone.0144663.ref003]\]. To ameliorate the survival of NSCLC patients, specific and sensitive prognostic factors for identifying cancer risk which can provide a more appropriate estimation of individual outcomes and allow the optimization of patient stratification are desired in clinical trials.

Existing researches have certified that systemic inflammation has a close relationship with malignancies \[[@pone.0144663.ref004]--[@pone.0144663.ref007]\]. Besides, patients' nutritional status is also closely linked to cancer mortality, with one third of deaths being caused by malnutrition rather than the cancer itself \[[@pone.0144663.ref008]\]. Thereafter, the predictive value for malignancies of combination of both systemic inflammation and nutritional status were increasingly investigated, such as Glasgow prognostic score (GPS) which defined as the combination of C-reactive protein (CRP) and albumin \[[@pone.0144663.ref009]\], Inflammatory-Nutritional Index (INI) which defined as ratio of albumin to CRP \[[@pone.0144663.ref010]\]. However, such kind of indexes were really scarce and dubious, and they were not tested routinely in clinical practice, especially in NSCLC.

As for systemic inflammation, cancer can induce local or systemic inflammation, which is mediated by activation of transcription factors and production of major inflammatory cytokines \[[@pone.0144663.ref011]\]. On the other hand, cancer-related inflammation can influence cell proliferation, cell survival, angiogenesis, tumor cell migration, invasion and metastasis of adaptive immunity \[[@pone.0144663.ref011]\]. Admittedly, neutrophil which is the most common and indispensable component of inflammation plays very important role in inflammatory tumor microenvironment \[[@pone.0144663.ref012]\]. Some studies have revealed derangement in the full blood count such as neutrophilia, was known poor independent prognostic factor for many solid tumors \[[@pone.0144663.ref013]--[@pone.0144663.ref015]\]. In addition, CRP which is the most widely accepted proxy for systemic inflammation was also identified as a prognostic factor in both advanced and resectable NSCLC \[[@pone.0144663.ref016], [@pone.0144663.ref017]\]. However, CRP is not commonly used in clinic because of low sensitivity and unconventional detection. Nutritional status of cancer patients, commonly reflected by serum albumin, is also a determinant of survival in many kinds of cancer. Hypoalbuminemia, an objective parameter of malnutrition \[[@pone.0144663.ref018]\], has been reported as a negative prognostic factor for survival in advanced NSCLC \[[@pone.0144663.ref019]\], and other malignancies \[[@pone.0144663.ref020], [@pone.0144663.ref021]\]. Nevertheless, the predictive efficiency of combination of pretreatment albumin level which reflects nutritional status and pretreatment neutrophil level which reflects systemic inflammation has not been reported before.

To find an index which can roundly and systematically reflect patients' condition, we put albumin and neutrophil together to form a new index named albumin and neutrophil combined prognostic grade (ANPG). The aim of this study was to investigate and validate our hypothesis that ANPG might be a new, convenient and more powerful predictive factor for NSCLC patients.

Patients and Methods {#sec006}
====================

Patient collection {#sec007}
------------------

A series of 1033 consecutive patients who underwent surgical treatment for primary NSCLC between January 2006 and September 2011 at the Department of Oncology of Shandong Provincial Hospital affiliated to Shandong University were retrospectively identified from the original electronic databases. Patient collection based on the following inclusion criteria: (1) patients who were pathologically diagnosed with NSCLC; (2) patients who underwent completely tumor resection; (3) patients who had complete serum albumin and neutrophil records before treatment within 1 week and (4) patients who had complete follow-up data. Patients were excluded who matched any of the following criteria: (1) patients who had ongoing non-cancer related inflammation, immunity disease or end-stage liver disease within 1 week; (2) patients who underwent previous chemotherapy and/or radiation therapy; (3) patients whose data were incomplete; (4) patients with previous or concomitant other cancers.

This research was approved by the Ethical Committee of Shandong Provincial Hospital affiliated to Shandong University and written informed consent was obtained by participants for their clinical records to be used in this study.

Clinical and follow-up data collection {#sec008}
--------------------------------------

Clinical characteristics including gender, age, histological subtype, degree of tumor differentiation, pathological TNM stage (pTNM), postoperative radiotherapy and/or chemotherapy, pretreatment albumin and neutrophil count were recorded for all patients. After surgical treatment, all patients were regularly followed-up by phone interview. The pTNM was carried out according to the 8th edition of the TNM classification \[[@pone.0144663.ref022]\]. The degree of tumor differentiation was obtained from pathological report.

Progression free survival (PFS) was calculated from the time when firstly definite diagnosis to progression or death of any cause. Overall survival (OS) was measured from the date on which the first time definite diagnosis was made or the date of surgery until the date of death for any cause, the date of loss to follow-up or the date on which the patient was last known to be alive.

Allocation of ANPG {#sec009}
------------------

Blood laboratory data, especially for albumin and neutrophil, was obtained before commencement of treatment. Three binary classification methods of pretreatment albumin and neutrophil were designed and the different cut-off points were as follows. (1) According to receiver operating characteristic (ROC) curve, the optimal cut-off values of pretreatment albumin and neutrophil were 42.55g/L and 2.895×10^9^/L not merely for OS but also for PFS, respectively. (2) The quartile values of pretreatment albumin and neutrophil were 43.80g/L and 3.070×10^9^/L, respectively. (3) The clinical reference values of pretreatment albumin and neutrophil were 35.00g/L and 7.000×10^9^/L, respectively.

The ANPG was calculated into 3 grades according to dichotomization of pretreatment albumin and neutrophil. Grade1 = elevated albumin and low neutrophil; grade2 = low albumin and low neutrophil, as well as elevated albumin and elevated neutrophil; grade3 = low albumin and elevated neutrophil.

Statistical analyses {#sec010}
--------------------

Statistical analyses were calculated by SPSS (version 20.0) software program (SPSS Inc., Chicago, IL, USA). Descriptive statistics were utilized to describe the characteristics of the study cohort. The optimal cut-off points were found out from ROC curve which is now widely recognized as the best approach for measuring the quality of diagnostic system. To ensure the best accuracy and diagnostic effect, the optimal cut-off value was located at the point on which the maximum absolute value \[sensitivity-(1-specificity)\] was calculated out. Kaplan-Meier (K-M) method was performed to determine the significance of variables for OS, PFS, and the log-rank test was utilized to examine the significant differences of survival distributions between different levels of albumin, neutrophil and ANPG. The Cox proportional hazards regression models were used for confirming the independent predictors of OS and PFS and multivariate Cox analyses were performed in a step-forward logistic regression approach. A two tailed *p*-value≤0.05 was considered to indicate a statistically significant difference.

Results {#sec011}
=======

Patients' characteristics {#sec012}
-------------------------

According to the inclusion criteria, a total of 1033 patients from the original files were finally retrospectively enrolled in our study. All samples were primary NSCLC patients who were pathologically diagnosed. Of these, the mean age was 59.18 years (range 20 to 83 years), and there were 745 (72.1%) patients ≤65years and 288 (27.9%) patients \>65years, with 741 (71.7%) males and 292 (28.3%) females. Mean albumin was 41.3 (range from 25.2 to 48.3) g/L and mean neutrophil count was 4.28 (range from 1.01 to 12.32) ×10^9^/L. According to ROC curve, the number of patients with low and high level pretreatment albumin was 614 (59.4%) and 419 (40.6%), respectively; low and high level pretreatment neutrophil was 205 (19.8%) and 828 (80.2%), respectively; grade1, grade2 and grade3 of ANPG was 93 (9.0%), 438 (42.4%) and 502 (48.6%), respectively. According to quartile values, 782 (75.7%) were low albumin level and 251 (24.3%) were high; 259 (25.1%) were low neutrophil level and 774 (74.9%) were high; 75 (7.3%) achieved grade1, 360 (34.8%) achieved grade2 and 598 (57.9%) achieved grade3 for ANPG. According to clinical reference values, only 61 (5.9%) patients were low albumin level; only 68 (6.6%) patients were high neutrophil level and only 7 (0.7%) patients achieved grade3 for ANPG. All of the main baseline characteristics are detailed in [Table 1](#pone.0144663.t001){ref-type="table"}.

10.1371/journal.pone.0144663.t001

###### Baseline characteristics of all 1033 NSCLC patients.

![](pone.0144663.t001){#pone.0144663.t001g}

                                            Characteristic                                                                Data (%)
  ----------------------------------------- -------------------------------------------------- -------------------------- -------------
                                            No. of patients                                                               1033 (100)
  According to the optimal cut-off values   Pretreatment albumin level (mean±sd, g/L)                                     41.3±3.67
                                                                                               Low                        614 (59.4)
                                                                                               High                       419 (40.6)
                                            Pretreatment neutrophil level (mean±sd, 10^9^/L)                              4.28±1.66
                                                                                               Low                        205 (19.8)
                                                                                               High                       828 (80.2)
                                            ANPG                                                                          
                                                                                               Grade1                     93 (9.0)
                                                                                               Grade2                     438 (42.4)
                                                                                               Grade3                     502 (48.6)
  According to quartile values              Pretreatment albumin level                                                    
                                                                                               Low                        782 (75.7)
                                                                                               High                       251 (24.3)
                                            Pretreatment neutrophil level                                                 
                                                                                               Low                        259 (25.1)
                                                                                               High                       774 (74.9)
                                            ANPG                                                                          
                                                                                               Grade1                     75 (7.3)
                                                                                               Grade2                     360 (34.8)
                                                                                               Grade3                     598 (57.9)
  According to clinical reference values    Pretreatment albumin level                                                    
                                                                                               Low                        61 (5.9)
                                                                                               High                       972 (94.1)
                                            Pretreatment neutrophil level                                                 
                                                                                               Low                        965 (93.4)
                                                                                               High                       68 (6.6)
                                            ANPG                                                                          
                                                                                               Grade1                     911 (88.2)
                                                                                               Grade2                     115 (11.1)
                                                                                               Grade3                     7 (0.7)
                                            Age (mean±sd, years)                                                          59.18±9.69
                                                                                               ≤65years                   745 (72.1)
                                                                                               \>65years                  288 (27.9)
                                            Gender                                                                        
                                                                                               Male                       741 (71.7)
                                                                                               Female                     292 (28.3)
                                            Postoperative radio-chemotherapy                                              
                                                                                               Yes                        325 (31.5)
                                                                                               No                         708 (68.5)
                                            pTNM                                                                          
                                                                                               Stage I,II                 721 (69.8)
                                                                                               Stage III                  312 (30.2)
                                            Differentiation                                                               
                                                                                               Well or moderate           716 (69.3)
                                                                                               Poor or undifferentiated   317 (30.7)
                                            Histological subtype                                                          
                                                                                               Adenocarcinoma             531 (51.4)
                                                                                               Squamous cell              428 (41.4)
                                                                                               Other                      74 (7.2)
                                            OS (mean±sd, month)                                                           44.29±23.63
                                            PFS (mean±sd, month)                                                          36.47±26.72

Abbreviations: OS,overall survival; PFS, progression free survival; HR, hazard risk; CI, confidence interval; ANPG, pretreatment albumin and neuprophil combined prognostic grade; pTNM, pathological TNM stage; sd, standard deviation.

Survival analyses in pretreatment albumin, neutrophil and ANPG {#sec013}
--------------------------------------------------------------

The median PFS of all patients was 31 months \[mean ± sd (standard deviation), 36.47±26.72\] and the median OS was 45 months (mean ± sd, 44.29±23.63) during all patients' follow-up period. 449 (43.5%) patients died and 563 (54.5%) patients made progression. K-M curves of pretreatment albumin, neutrophil levels and ANPG for OS and PFS according to optimal cut-off values, quartile values and clinical reference values were shown in [Fig 1](#pone.0144663.g001){ref-type="fig"}, [Fig 2](#pone.0144663.g002){ref-type="fig"}, [Fig 3](#pone.0144663.g003){ref-type="fig"}, respectively. Patients with high pretreatment albumin had a significantly better OS and PFS than low group (*p*\<0.05) while it lost its significance for clinical cut-off determination. Moreover, OS and PFS rate for patients with high pretreatment neutrophil were worse than low group (all *p*\<0.05). There was also a significant different survival in different ANPG grades both for OS and PFS (all *p*\<0.05).

![Kaplan-Meier curves for optimal cut-off values.\
The OS according to different pretreatment albumin levels, neutrophil levels and ANPG grades is shown in A, B, C, respectively. The PFS according to different pretreatment albumin levels, neutrophil levels and ANPG grades is shown in D, E, F, respectively.](pone.0144663.g001){#pone.0144663.g001}

![Kaplan-Meier curves for quartile values.\
The OS according to different pretreatment albumin levels, neutrophil levels and ANPG grades is shown in A, B, C, respectively. The PFS according to different pretreatment albumin levels, neutrophil levels and ANPG grades is shown in D, E, F, respectively.](pone.0144663.g002){#pone.0144663.g002}

![Kaplan-Meier curves for clinical reference values.\
The OS according to different pretreatment albumin levels, neutrophil levels and ANPG grades is shown in A, B, C, respectively. The PFS according to different pretreatment albumin levels, neutrophil levels and ANPG grades is shown in D, E, F, respectively.](pone.0144663.g003){#pone.0144663.g003}

Univariate survival analyses {#sec014}
----------------------------

All the results of univariate survival analyses were shown in [Table 2](#pone.0144663.t002){ref-type="table"}.

10.1371/journal.pone.0144663.t002

###### Univariate analyses.

![](pone.0144663.t002){#pone.0144663.t002g}

                                                                                                          OS                     PFS                              
  ----------------------------------------- ---------------------------------- -------------------------- ---------------------- --------- ---------------------- ---------
  According to the optimal cut-off values   Albumin                                                                                                               
                                                                               High level                 1                                1                      
                                                                               Low level                  1.699 (1.392--2.074)   \<0.001   1.433 (1.205--1.704)   \<0.001
                                            Neutrophil                                                                                                            
                                                                               Low level                  1                                1                      
                                                                               High level                 1.714 (1.313--2.238)   \<0.001   1.511 (1.206--1.893)   \<0.001
                                            ANPG                                                                                                                  
                                                                               Grade 1                    1                                1                      
                                                                               Grade 2                    1.830 (1.162--2.882)   0.009     1.582 (1.103--2.270)   0.013
                                                                               Grade 3                    2.987 (1.914--4.660)   \<0.001   2.206 (1.548--3.145)   \<0.001
  According to quartile values              Albumin                                                                                                               
                                                                               High level                 1                                1                      
                                                                               Low level                  1.478 (1.171--1.864)   0.001     1.329 (1.088--1.625)   0.005
                                            Neutrophil                                                                                                            
                                                                               Low level                  1                                1                      
                                                                               High level                 1.384 (1.103--1.736)   0.005     1.341 (1.099--1.636)   0.004
                                            ANPG                                                                                                                  
                                                                               Grade 1                    1                                1                      
                                                                               Grade 2                    1.409 (0.899--2.209)   0.135     1.287 (0.884--1.873)   0.188
                                                                               Grade 3                    1.980 (1.283--3.056)   0.002     1.709 (1.189--2.455)   0.004
  According to clinical reference values    Albumin                                                                                                               
                                                                               High level                 1                                1                      
                                                                               Low level                  1.356 (0.946--1.943)   0.097     1.204 (0.855--1.696)   0.287
                                            Neutrophil                                                                                                            
                                                                               Low level                  1                                1                      
                                                                               High level                 1.489 (1.068--2.077)   0.019     1.470 (1.084--1.993)   0.013
                                            ANPG                                                                                                                  
                                                                               Grade 1                    1                                1                      
                                                                               Grade 2                    1.414 (1.081--1.849)   0.011     1.362 (1.063--1.744)   0.015
                                                                               Grade 3                    1.911 (0.713--5.119)   0.198     1.399 (0.523--3.743)   0.504
                                            Postoperative radio-chemotherapy                                                                                      
                                                                               No                         1                                1                      
                                                                               Yes                        1.535 (1.271--1.854)   \<0.001   1.476 (1.245--1.749)   \<0.001
                                            Gender                                                                                                                
                                                                               Female                     1                                1                      
                                                                               Male                       1.281 (1.035--1.586)   0.023     1.215 (1.007--1.466)   0.042
                                            Age                                                                                                                   
                                                                               ≤65years                   1                                1                      
                                                                               \>65years                  1.360 (1.118--1.655)   0.002     1.195 (0.999--1.430)   0.051
                                            pTNM                                                                                                                  
                                                                               Stage I,II                 1                                1                      
                                                                               Stage III                  3.148 (2.611--3.796)   \<0.001   2.360 (1.994--2.794)   \<0.001
                                            Differentiation                                                                                                       
                                                                               well or moderate           1                                1                      
                                                                               poor or undifferentiated   1.420 (1.171--1.721)   \<0.001   1.319 (1.108--1.571)   0.002
                                            Histological subtype                                                                                                  
                                                                               Adenocarcinoma             1                                1                      
                                                                               Squamous cell              1.248 (1.031--1.512)   0.023     1.054 (0.888--1.252)   0.546
                                                                               Other                      1.025 (0.695--1.511)   0.903     0.861 (0.606--1.223)   0.403

Abbreviations: OS,overall survival; PFS, progression free survival; HR, hazard risk; CI, confidence interval; ANPG, pretreatment albumin and neuprophil combined prognostic grade; pTNM, pathological TNM stage.

As for ROC cut-off determination, low pretreatment albumin level \[hazard ratio (HR) = 1.699, 95% confidence interval (CI): 1.392--2.074, *p*\<0.001\], high pretreatment neutrophil level (HR = 1.714, 95%CI: 1.313--2.238, *p*\<0.001), high ANPG (HR = 1.830, 95%CI: 1.162--2.882, *p* = 0.009, grade2/grade1; HR = 2.987, 95%CI: 1.914--4.660, *p*\<0.001, grade3/grade1) were associated with worse OS. As for quartile cut-off determination, low albumin level (HR = 1.478, 95%CI: 1.171--1.864, *p* = 0.001), high neutrophil level (HR = 1.384, 95%CI: 1.103--1.736, *p* = 0.005), high ANPG (HR = 1.409, 95%CI: 0.899--2.209, *p* = 0.135, grade2/grade1; HR = 1.980, 95%CI: 1.283--3.056, *p* = 0.002, grade3/grade1) were also proved to be poor outcome factors for OS. As for clinical cut-off determination, only high neutrophil level (HR = 1.489, 95%CI: 1.068--2.077, *p* = 0.019) and grade2 of ANPG (HR = 1.414, 95%CI: 1.081--1.849, *p* = 0.011, grade2/grade1) retained significance for OS. In the analyses about PFS, the HRs for ANPG were also generally higher than pretreatment albumin and neutrophil levels according ROC and quartile cut-off determinations, implying more important prognostic value. Other identified prognostic factors for OS and PFS including postoperative radio-chemotherapy, gender, age, pTNM, degree of tumor differentiation (all *p*\<0.05). Of note, age\>65years was only a nearly univariate prognostic predictor for PFS (*p* = 0.051) and histological subtype only significantly predicted for OS (HR = 1.248, 95%CI: 1.031--1.512, *p* = 0.023, squamous cell/adenocarcinoma).

Multivariate survival analyses {#sec015}
------------------------------

The multivariate Cox proportional regression in which variables were tested in a step-forward logistic regression approach was performed to examine independent factors for OS and PFS. Pretreatment albumin level, pretreatment neutrophil level and ANPG were respectively brought into the model with all other significant factors in univariate survival analyses. Results of the three multivariate survival analyses were successively shown in [Table 3](#pone.0144663.t003){ref-type="table"}.

10.1371/journal.pone.0144663.t003

###### Multivariate analyses.

![](pone.0144663.t003){#pone.0144663.t003g}

                                                  According to the optimal cut-off values   According to quartile values                                                                                                                                               
  ---------------------------------- ------------ ----------------------------------------- ------------------------------ --------------------------------------- --------- --------------------------------------- --------- --------------------------------------- ---------
  Albumin                                                                                                                                                                                                                                                              
                                     High level   1                                                                        1                                                 1                                                 1                                       
                                     Low level    1.645 (1.347--2.009)                      \<0.001                        1.417 (1.191--1.687)                    \<0.001   1.325 (1.048--1.675)                    0.019     1.259 (1.028--1.541)                    0.026
  Age                                                                                                                                                                                                                                                                  
                                     ≤65years     1                                                                        1                                                 1                                                 1                                       
                                     \>65years    1.601 (1.310--1.958)                      \<0.001                        1.366 (1.111--1.605)                    0.002     1.605 (1.311--1.963)                    \<0.001   1.353 (1.125--1.626)                    0.001
  pTNM                                                                                                                                                                                                                                                                 
                                     Stage I,II   1                                                                        1                                                 1                                                 1                                       
                                     Stage III    3.260 (2.680--3.966)                      \<0.001                        2.367 (1.984--2.823)                    \<0.001   3.403 (2.812--4.119)                    \<0.001   2.350 (1.970--2.803)                    \<0.001
  Postoperative radio-chemotherapy                                                                                                                                                                                                                                     
                                     No           1                                                                        1                                                 [\*](#t003fn002){ref-type="table-fn"}             1                                       
                                     Yes          1.229 (1.011--1.493)                      0.038                          1.249 (1.048--1.488)                    0.013     [\*](#t003fn002){ref-type="table-fn"}             1.245 (1.045--1.484)                    0.014
  Gender                                                                                                                                                                                                                                                               
                                     Female       [\*](#t003fn002){ref-type="table-fn"}                                    [\*](#t003fn002){ref-type="table-fn"}             1                                                 [\*](#t003fn002){ref-type="table-fn"}   
                                     Male         [\*](#t003fn002){ref-type="table-fn"}                                    [\*](#t003fn002){ref-type="table-fn"}             1.278 (1.031--1.583)                    0.025     [\*](#t003fn002){ref-type="table-fn"}   
  Neutrophil                                                                                                                                                                                                                                                           
                                     Low level    1                                                                        1                                                 1                                                 1                                       
                                     High level   1.639 (1.255--2.141)                      \<0.001                        1.439 (1.147--1.804)                    0.002     1.349 (1.076--1.692)                    0.01      1.297 (1.062--1.583)                    0.011
  Age                                                                                                                                                                                                                                                                  
                                     ≤65years     1                                                                        1                                                 1                                                 1                                       
                                     \>65years    1.639 (1.324--2.001)                      \<0.001                        1.373 (1.143--1.648)                    0.001     1.665 (1.364--2.033)                    \<0.001   1.386 (1.154--1.663)                    \<0.001
  pTNM                                                                                                                                                                                                                                                                 
                                     Stage I,II   1                                                                        1                                                 1                                                 1                                       
                                     Stage III    3.390 (2.802--4.101)                      \<0.001                        2.365 (1.983--2.821)                    \<0.001   3.403 (2.813--4.117)                    \<0.001   2.366 (1.985--2.822)                    \<0.001
  Postoperative radio-chemotherapy                                                                                                                                                                                                                                     
                                     No           [\*](#t003fn002){ref-type="table-fn"}                                    1                                                 [\*](#t003fn002){ref-type="table-fn"}             1                                       
                                     Yes          [\*](#t003fn002){ref-type="table-fn"}     　                             1.213 (1.017--1.445)                    0.031     [\*](#t003fn002){ref-type="table-fn"}             1.225 (1.028--1.459)                    0.023
  ANPG                                                                                                                                                                                                                                                                 
                                     Grade 1      1                                                                        1                                                 1                                                 1                                       
                                     Grade 2      1.771 (1.124--2.792)                      0.014                          1.493 (1.039--2.145)                    0.03      1.538 (0.980--2.413)                    0.061     1.323 (0.908--1.928)                    0.145
                                     Grade 3      2.790 (1.786--4.359)                      \<0.001                        2.065 (1.445--2.950)                    \<0.001   1.922 (1.244--2.969)                    0.003     1.638 (1.139--2.357)                    0.008
  Age                                                                                                                                                                                                                                                                  
                                     ≤65years     1                                                                        1                                                 1                                                 1                                       
                                     \>65years    1.570 (1.284--1.919)                      \<0.001                        1.318 (1.097--1.584)                    0.003     1.165 (1.321--1.974)                    \<0.001   1.346 (1.120--1.617)                    0.002
  pTNM                                                                                                                                                                                                                                                                 
                                     Stage I,II   1                                                                        1                                                 1                                                 1                                       
                                     Stage III    3.385 (2.797--4.095)                      \<0.001                        2.364 (1.982--2.820)                    \<0.001   3.381 (2.793--4.094)                    \<0.001   2.349 (1.969--2.803)                    \<0.001
  Postoperative radio-chemotherapy                                                                                                                                                                                                                                     
                                     No           [\*](#t003fn002){ref-type="table-fn"}                                    1                                                 [\*](#t003fn002){ref-type="table-fn"}             1                                       
                                     Yes          [\*](#t003fn002){ref-type="table-fn"}                                    1.219 (1.022--1.453)                    0.027     [\*](#t003fn002){ref-type="table-fn"}             1.227 (1.030--1.462)                    0.022

Abbreviations: OS,overall survival; PFS, progression free survival; HR, hazard risk; CI, confidence interval; ANPG, pretreatment albumin and neuprophil combined prognostic grade; pTNM, pathological TNM stage.

\* Not in the final step of multivariate analyses.

As for ROC cut-off determination, pretreatment albumin level, pretreatment neutrophil level, ANPG were all significantly independent prognostic factors (*p*\<0.05) and ANPG \[HR = 1.771(grade2/grade1), HR = 2.790(grade3/grade1) for OS; HR = 1.493(grade2/grade1), HR = 2.065(grade3/grade1) for PFS\] presented higher HR than albumin (HR = 1.645 for OS; HR = 1.417 for PFS) and neutrophil (HR = 1.639 for OS; HR = 1.439 for PFS). Age and pTNM were also independently prognostic for OS and PFS (all *p*\<0.05). Noteworthily, postoperative radio-chemotherapy was also an independent predictor but it had no significant impact on OS when it was analyzed with neutrophil or ANPG.

As for quartile cut-off determination, pretreatment albumin level, pretreatment neutrophil level, ANPG (grade3/grade1) were also significantly independent prognostic factors (*p*\<0.05). ANPG \[HR = 1.538(grade2/grade1), HR = 1.922(grade3/grade1) for OS; HR = 1.323(grade2/grade1), HR = 1.638(grade3/grade1) for PFS\] still presented higher HR than albumin (HR = 1.325 for OS; HR = 1.259 for PFS) and neutrophil (HR = 1.349 for OS; HR = 1.297 for PFS). Age and pTNM were also independently prognostic for OS and PFS (all *p*\<0.05). Besides, postoperative radio-chemotherapy only had significantly independent impact on PFS instead of OS. Gender was also proved to be an independent predictor for OS when it was analyzed with pretreatment albumin level (*p* = 0.025).

Pretreatment albumin level, pretreatment neutrophil level and ANPG were not included in the final step of multivariate analyses according to clinical cut-off determination (not shown in [Table 3](#pone.0144663.t003){ref-type="table"}).

Discussion {#sec016}
==========

Since high mortality and dissatisfactory improvement of lung cancer, the major prognostic factors have been searched all the time and numerous clinical indexes were identified to be significantly related to lung cancer survival. It has been reported systemic inflammation and nutritional status were closely related to NSCLC \[[@pone.0144663.ref007], [@pone.0144663.ref023]\]. The connection between inflammation and survival of NSCLC dates back to early of 21 century \[[@pone.0144663.ref024]\]. After decade years, mounting reports have provided solid evidence to prove prognostic value of systemic inflammation and nutritional status which can be easily quantified and reflected by peripheral neutrophil and serum albumin \[[@pone.0144663.ref013], [@pone.0144663.ref019]\]. In our study, we firstly took albumin and neutrophil together to evaluate whether the combination of them could present a better predictive value for NSCLC patients' survival. Strikingly, we found ANPG not only was a strong independent predictor but also had a higher sensitivity than either of them.

Neutrophil, an important component of inflammation, is the first type of immune cell that responds to the site of infection and attack invaders directly. Actually, neutrophil guards its conventional positive character as a defender by killing not only invading pathogens but also malignancies. However, the inflammatory cells and cytokines found in tumors are more likely to contribute to tumor growth, progression, and immunosuppression than they are to mount an effective host antitumor response \[[@pone.0144663.ref025]\]. In 1986, Shoenfeld and colleagues found that high peripheral blood leukocyte count indicated worse prognosis in patients with non-hematologic neoplasms \[[@pone.0144663.ref026]\]. Thereafter, an increasing number of studies demonstrated neutrophil was related to poor outcome in multiple tumors \[[@pone.0144663.ref027]\], also in NSCLC \[[@pone.0144663.ref013]\]. These early reports were consistent with our findings in this study that high pretreatment neutrophil level was associated with worse survival in NSCLC patients. Although exact mechanism for this remains unclear, the reason may be that neutrophils can be recruited by kinds of chemoattractant mediators into tumor microenvironment then become pro-tumor N2 phenotype tumor-infiltrating neutrophil (N2-TIN) which can improve tumor progression \[[@pone.0144663.ref012], [@pone.0144663.ref028]\]. Albumin, which is produced by liver, is usually regarded as an index of malnutrition and cachexia when decreased. Evidence suggested that inflammation could suppress albumin synthesis \[[@pone.0144663.ref029]\] and the progressive decrease of albumin was a consequence of systemic inflammation \[[@pone.0144663.ref030]\]. As another inflammatory index, hypoalbuminemia was also reported to be associated with poor survival in NSCLC \[[@pone.0144663.ref019]\]. We speculated the predict value of low pretreatment albumin might be due to dystrophic, lack of immunity and weak status of body. Moreover, chemotherapeutics may remain high residue and high toxicity in the blood stream because of lacking of albumin to bind to the drugs and this may also contribute to cancer mortality. However, both of pretreatment albumin and neutrophil levels have not been commonly used in clinic because of their low predict efficiency. The volatility of albumin also limits its application in clinic. Therefore, we gave a hypothesis here that taking pretreatment albumin and neutrophil together, ANPG would be a more powerful and feasible predictor for NSCLC patients. Additionally, other researches referring to this combined prognosis score is really scarce, especially for NSCLC.

In this study, we firstly explored the prognostic value of the combination of serum albumin and neutrophil in NSCLC patients. Our results suggested that when adopting ROC and quartile cut-off determinations for dichotomy of albumin and neutrophil, patients with low pretreatment albumin, elevated pretreatment neutrophil, high ANPG grade had worse OS and PFS in certain extent. Although all three of them were independently related to poor survival outcomes, ANPG offered higher HRs than the two other indexes, which supported our hypothesis that ANPG presented more powerful prognostic value in univariate and multivariate analyses.

When using clinical cut-off determination, pretreatment albumin lost its significance on predicting outcome for NSCLC, and ANPG was also disqualified for independent prognostic factor in multivariate analyses. This might be due to serious maldistribution of dichotomy and tiny sample size of low albumin level, high neutrophil level and grade3 (ANPG). Besides, for patients initially diagnosed as primary lung cancer, most haematoglgical parameters of them had not changed too much and were still in normal clinical reference range. Therefore, the clinical reference cut-off values may not be suitable for dichotomy of these patients. Even so, K-M curve and survival data indicated that there still existed worse prognostic trend for patients with low pretreatment level, high pretreatment level and high ANPG grade ([Fig 3](#pone.0144663.g003){ref-type="fig"}).

Noteworthily, haematological tests are one of the routine kinds of tests carried out in cancer patients, and the ANPG will be easily obtained in clinic. Compared with existing factors, our study might provide a new, highly reproducible, easily obtainable, low cost and most of all more powerful index for predicting outcome and making therapeutic decisions. Even so, the authentic value of ANPG should be confirmed in clinic. Moreover, what we have discovered did not clarify precise mechanism underlying the relationship between this combined index and NSCLC prognosis. Further studies are required to address this question.

Conclusion {#sec017}
==========

Our study firstly established a new index named ANPG for predicting outcome of primary NSCLC after surgical treatment by putting pretreatment albumin and neutrophil together. We not only demonstrated ANPG was an significantly independent prognostic factor for NSCLC patients and patients with high ANPG seemed to have more chance to live in poor prognosis, but also found ANPG outperformed better than either albumin or neutrophil for predicting outcome and making therapeutic decisions for NSCLC. However, the potential mechanisms and performance for clinical practice should be validated in further prospective studies.
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